JPRN-UMIN000022514Completed未知
Single arm open-label study to evaluate efficacy and safety of low intensity extracorporeal shockwave therapy in prostate cancer patients with ED after radical prostatectomy - Study to evaluate efficacy and safety of low intensity extracorporeal shockwave therapy in patients with ED after radical prostatectomy
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Hiroshima University
- Enrollment
- 50
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 40years-old to 80years-old (—)
- Sex
- Male
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1) Patient with spinal injury, chronic blood disease, and anatomic anomaly of penile vessels. 2) Patient with endocrine, mental or psychologic disease caused of erectile dysfunction. 3) Patients with past history of ischemic heart disease, cerebral hemorrhage, cerebral infarction and fetal arrhythmia, or who can not withdraw hemagogic drugs such as aspirin and warfarin. 4) Patients with cardiovascular disease prohibited to the sexual intercourse. 5) Patients have sexually transmitted infection and penile abscess. 6) Patients using nitrate drugs such as Nitroglycerin. 7) Patients judged not to appropriate to this study by the doctor in charge of this study.
Investigators
Similar Trials
Active, not recruiting
Not Applicable
A single arm, open label study to assess the efficacy, safety and tolerability of once-monthly administration of subcutaneous C.E.R.A. for the maintenance of haemoglobin levels in pre-dialysis patients with chronic renal anaemia - ORIOChronic renal anaemiaMedDRA version: 9.1Level: LLTClassification code 10058123Term: Renal anaemiaEUCTR2008-003173-40-ITROCHE
Active, not recruiting
Not Applicable
A single arm, open label study to assess the efficacy, safety and tolerability of once- monthly administration of intravenous C.E.R.A. for the maintenance of haemoglobin levels in dyalysis patients with chronic renal anaemia - N/AEUCTR2006-006349-15-GRRoche (HELLAS) SA
Active, not recruiting
Phase 1
A single arm, open label study to assess the efficacy, safety, and tolerability of monthly administration of RO0503821 for the treatment of chronic renal anaemia in patients not on dialysis and not currently treated with ESA.EUCTR2006-006707-36-FIRoche Oy200
Active, not recruiting
Not Applicable
A single arm, open label study to assess the efficacy, safety, and tolerability of monthly administration of subcutaneous RO0503821 for the treatment of chronic renal anaemia in patients not on dialysis and not currently treated with ESA.Chronic renal anaemiaMedDRA version: 9.1Level: LLTClassification code 10058123Term: Renal anaemiaEUCTR2006-006707-36-EERoche Oy200
Completed
Phase 4
A clinical trial to assess the effect, safety and tolerability of MIRCERA administered intravenously or subcutaneously once in a month for the maintainance of Haemoglobin levels in dialysis patients with chronic renal anaemiaCTRI/2009/091/000455Roche Products (India) Pvt.Ltd, India170